CDH2 and breast carcinoma: In this study, we found that AESN could attenuate N-cadherin, vimentin, and ZEB1 levels of MCF-7 breast cancer cells after 24 h treatment (Figure 7), revealing that AESN may demonstrate chemotherapy resistance, metastasis, and cancer cell migration as well as suppress cancer cell proliferation [1,5,6].